Loading…
Dare Bioscience, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in DARE.
▼ -95.6% over 5Y.
today you would have $38.70▼ -96.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.93 | $3.12 | $3.71 | $9.96 | $24.00 | $16.08 | $9.84 | $8.53 | $25.97 | $84.96 | $336.00 | $746.40 | |
| P/E | — | — | — | — | — | — | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| CABRCaring Brands, Inc. | $1.39 | — | — | — | -333.74% | $14.41M |
| RGNTRegentis Biomaterials Ltd | $2.00 | — | 2.2x | — | — | $14.05M |
| PASGPassage BIO, Inc. | $4.52 | — | 3.3x | — | -169.09% | $14.54M |
| INTSIntensity Therapeutics Inc | $4.25 |
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. It has a strategic collaboration with MyMenopauseRx. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Company description provided by Yahoo Finance.
| 0.6x |
| — |
| — |
| — |
| P/S | 27.1x | 27.3x | 2822.3x | 11.1x | 7.2x | — | — | — | — | — | 26.8x | — | 1584.2x |
| P/B | 4.3x | 9.9x | — | — | 6.4x | 4.3x | — | 45.9x | 1.2x | 1.9x | — | — | 2.8x |
| EPS | -$1.20 | -$0.48 | -$4.15 | -$4.44 | -$7.56 | -$10.92 | -$11.64 | -$18.84 | $42.72 | -$9.72 | -$187.20 | -$192.00 |
| Profit margin | -1187.41% | -1300.66% | -41430.90% | -1074.17% | -309.48% | — | — | — | — | — | -87.82% | — | -29177.50% |
| ROE | -248.84% | -471.37% | — | — | -278.50% | -99.85% | — | -3235.71% | -248.84% | -86.54% | — | — | -51.50% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 1.4x |
| — |
| -195.88% |
| $13.88M |
| HSCSHeartSciences Inc. | $3.03 | — | 42.7x | — | -4239.91% | $13.65M |
| ICUSeaStar Medical Holding Corp | $3.09 | — | 3.1x | — | -356.87% | $13.62M |